Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Jeffrey S. Berger, François Laliberté, Akshay Kharat, Dominique Lejeune, Kenneth Todd Moore, Young Jung, Patrick Lefebvre & Veronica Ashton. (2021) Healthcare resource utilization and costs of rivaroxaban versus warfarin among non-valvular atrial fibrillation (NVAF) patients with obesity in a US population. Journal of Medical Economics 24:1, pages 550-562.
Read now
Read now
Dejan Milentijevic, Guillaume Germain, François Laliberté, Brahim K. Bookhart, Sean D. MacKnight, Jenkin Tsang & Patrick Lefebvre. (2020) Healthcare costs of NVAF patients treated with rivaroxaban and apixaban in the US. Journal of Medical Economics 23:11, pages 1365-1374.
Read now
Read now
Alpesh Amin, Allison Keshishian, Jeffrey Trocio, Oluwaseyi Dina, Hannah Le, Lisa Rosenblatt, Xianchen Liu, Jack Mardekian, Qisu Zhang, Onur Baser & Lien Vo. (2017) Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population. Current Medical Research and Opinion 33:9, pages 1595-1604.
Read now
Read now
Lin Xie, Lien Vo, Allison Keshishian, Kwanza Price, Prianka Singh, Jack Mardekian, Amanda Bruno, Onur Baser, Jully Kim, Wilson Tan & Jeffrey Trocio. (2016) Comparison of hospital length of stay and hospitalization costs among patients with non-valvular atrial fibrillation treated with apixaban or warfarin: An early view. Journal of Medical Economics 19:8, pages 769-776.
Read now
Read now
Amanda M. Farr, Yonghua Jing, Stephen Johnston, Jeffrey Trocio, Shalabh Singhal, Amanda Bruno & John Graham. (2015) Comparison of hospital length of stay between hospitalized non-valvular atrial fibrillation patients treated with either apixaban or warfarin. Hospital Practice 43:3, pages 172-179.
Read now
Read now
Alpesh Amin, Amanda Bruno, Jeffrey Trocio, Jay Lin & Melissa Lingohr-Smith. (2015) Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US. Journal of Medical Economics 18:6, pages 399-409.
Read now
Read now
Articles from other publishers (6)
Michael Situ, Ute I. Schwarz, Guangyong Zou, Eric McArthur, Richard B. Kim, Amit X. Garg & Sisira Sarma. (2023) Does prescribing apixaban or rivaroxaban versus warfarin for patients diagnosed with atrial fibrillation save health system costs? A multivalued treatment effects analysis. The European Journal of Health Economics.
Crossref
Crossref
Jeffrey S. Berger, Veronica Ashton, François Laliberté, Guillaume Germain, Brahim Bookhart, Dominique Lejeune, Julien Boudreau, Patrick Lefebvre & Matthew R. Weir. (2023) Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Non-valvular Atrial Fibrillation (NVAF) Patients with Diabetes in a US Population. Advances in Therapy 40:3, pages 1224-1241.
Crossref
Crossref
François Laliberté, Veronica Ashton, Akshay Kharat, Dominique Lejeune, Kenneth Todd Moore, Young Jung, Patrick Lefebvre & Jeffrey S Berger. (2021) Economic burden of rivaroxaban and warfarin among nonvalvular atrial fibrillation patients with obesity and polypharmacy. Journal of Comparative Effectiveness Research 10:16, pages 1235-1250.
Crossref
Crossref
Katherine VilainHaiyan LiWingham J. KwongElliott M. AntmanChristian T. RuffEugene Braunwald, David J. Cohen, Robert P. GiuglianoElizabeth A. Magnuson. (2020) Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF–TIMI 48 Trial. Circulation: Cardiovascular Quality and Outcomes 13:11.
Crossref
Crossref
Jeff R. Schein, C. Michael White, Winnie W. Nelson, Jeffrey Kluger, Elizabeth S. Mearns & Craig I. Coleman. (2016) Vitamin K antagonist use: evidence of the difficulty of achieving and maintaining target INR range and subsequent consequences. Thrombosis Journal 14:1.
Crossref
Crossref
Erin R. Weeda, Christine G. Kohn, W. Frank Peacock, Gregory J. Fermann, Concetta Crivera, Jeff R. Schein & Craig I. Coleman. (2016) Rivaroxaban versus Heparin Bridging to Warfarin Therapy: Impact on Hospital Length of Stay and Treatment Costs for Low-Risk Patients with Pulmonary Embolism. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 36:10, pages 1109-1115.
Crossref
Crossref